利妥昔单抗治疗原发性胆汁性胆管炎疲劳无效:一项2期随机对照试验
这项单中心2期随机对照试验纳入57例伴中重度疲劳的原发性胆汁性胆管炎(PBC)患者,随机接受利妥昔单抗(1000 mg,两剂)或生理盐水安慰剂。主要终点为3个月时PBC-40疲劳域评分,两组均有改善但无显著差异(校正均数差-0.9,95%CI -4.6至3.1)。结论认为利妥昔单抗在12个月研究期内安全,但对PBC疲劳无效。
要点
- 利妥昔单抗对PBC疲劳无效:3个月PBC-40疲劳域评分两组均改善,校正均数差-0.9(95%CI -4.6至3.1),无显著差异。
- 利妥昔单抗组仅见无氧阈值改善,但与疲劳改善无关。
- 12个月研究期内未见治疗相关严重不良事件。
核心结论
- 利妥昔单抗在12个月研究期内安全,但无证据表明对PBC疲劳有效。
- 利妥昔单抗组见无氧阈值改善,可能将AMA与肌肉生物能量学功能障碍联系起来,但这与疲劳改善无关。
- 在这一以熊去氧胆酸(UDCA)应答为主、早期疾病阶段的队列中,利妥昔单抗对碱性磷酸酶水平有一些有益作用的证据。
研究设计与样本
- 单中心2期随机对照试验,57例18岁及以上伴中重度疲劳的PBC患者随机接受利妥昔单抗(1000 mg)两剂或生理盐水(安慰剂)两剂。
- 主要终点为3个月时采用PBC-40疲劳域评估的疲劳严重程度。
- 次要终点包括患者报告结局及免疫学和生物能量学疾病参数,实验性终点包括疾病严重程度的生化标志物。
主要发现
- 3个月时疲劳评分两组均有改善,无显著差异(校正均数差-0.9,95%CI -4.6至3.1)。
- 其他患者报告结局或体力活动方面差异很小。
- 无氧阈值改善仅见于利妥昔单抗组,但与疲劳改善无关。
- 未见治疗相关严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. Half of patients experience debilitating fatigue, which is currently untreatable. Previous studies have shown muscle bioenergetic abnormalities in PBC, including increased muscle acidosis with exercise linked to the antimitochondrial antibody (AMA) diagnostic of the disease, and reduced anaerobic threshold. In this study we addressed the hypothesis that fatigue in PBC is driven by muscle bioenergetic abnormality related to AMA, and that AMA reduction with B-cell depletion therapy will improve fatigue. In our single-center phase 2 randomized controlled trial, 57 participants aged 18 years or older with PBC and moderate to severe fatigue were randomized to receive two doses of either rituximab (1000 mg) or saline (placebo). The primary outcome measure was fatigue severity assessed using the PBC-40 fatigue domain at 3 months. Secondary outcome measures included patient-reported outcomes and immunological and bioenergetics disease parameters. Experimental outcomes included biochemical markers of disease severity. Improvement in fatigue score at 3 months was seen in both arms, with no significant difference (adjusted mean difference -0.9 [95% confidence interval -4.6 to 3.1]). Little difference was observed in other patient-reported outcomes or physical activity. Significant anaerobic threshold improvement was seen in the rituximab group, only but this was not associated with fatigue improvement. No treatment-emergent serious adverse events were seen. Conclusions: Rituximab was safe over the 12-month study period but showed no evidence of effectiveness for the treatment of fatigue in PBC. Anaerobic threshold improvement was seen, potentially linking AMA with muscle bioenergetics dysfunction; however, this was not related to improvement in fatigue. Rituximab had some evidence of a beneficial effect on alkaline phosphatase levels in this largely ursodeoxycholic acid (UDCA)-responding, early-disease stage cohort. (Hepatology 2018; 00:000-000).
引用
- Khanna A, Jopson L, Howel D, et al. Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2018. PMID: 29790196. doi:10.1002/hep.30099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。